AMT 061

Drug Profile

AMT 061

Alternative Names: AMT-061

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator uniQure
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor IX stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 14 Nov 2017 Phase-I/II clinical trials in Haemophilia B in Netherlands (IV) (uniQure pipeline, November 2017)
  • 19 Oct 2017 uniQure plans a pivotal clinical trial for Haemophilia B in USA and the European Union in the third quarter of 2018
  • 19 Oct 2017 uniQure plans a short dose-confirmation clinical trial for Haemophilia B in the third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top